secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001818331-23-000041
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q1 2023 pro forma revenue $40.7M (+7% YoY); exome revenue up 22% to $22.4M; reaffirms FY guidance
--------------------------------------------------------------------------------

- Pro forma revenue from continuing ops $40.7M, up 7% YoY; whole exome/genome test revenue $22.4M, up 22%.
- Adjusted gross margin from continuing ops 34%; total company cash burn improved 31% YoY to $58.8M.
- Net loss ($60.4)M; adjusted net loss ($48.9)M, improvement of 23% YoY.
- Reaffirms FY2023 guidance: revenue $205-220M, cash burn $95-110M for continuing ops, profitable in 2025.
- Completed $150M public offering; appointed Devin K. Schaffer as General Counsel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833123000041/0001818331-23-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833123000041/smfr-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001818331-23-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer